[1] Murthy VL, Desai NR, Vora A, et al. Increasing proportion of clinical trials using noninferiority end points. Clinical cardiology 2012;35:522–23 10.1002/clc.22040 [22806427]

[2] Mauri L, D'Agostino RB. Challenges in the Design and Interpretation of Noninferiority Trials. N Engl J Med 2017;377:1357–67 10.1056/NEJMra1510063 [28976859]

[3] Blackwelder WC. "Proving the null hypothesis" in clinical trials. Controlled Clinical Trials 1982;3:345–53 10.1016/0197-2456(82)90024-1 [7160191]

[4] Beyer-Westendorf J, Schellong SM, Gerlach H, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. The Lancet Haematology 2017;4:e105-e113 10.1016/S2352-3026(17)30014-5

[5] Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018;378:615–24 10.1056/NEJMoa1711948 [29231094]

[6] Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019;380:415–24 10.1056/NEJMoa1808312 [30152252]

[7] A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118–23 10.1056/NEJM199710163371603 [9340503]

[8] Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682–87 10.1056/NEJM199603143341102 [8594426]

[9] Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92 10.1056/NEJMoa1107039 [21870978]

[10] Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010;363:1222–32 10.1056/NEJMoa0912072 [20860504]

[11] Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53 10.1056/NEJMoa025313 [12853587]

[12] Pérard L, Hot A, Cucherat M, et al. Essais de non-infériorité dans la maladie thromboembolique veineuse. Une lecture critique est nécessaire! La Revue de medecine interne 2007;28:731–36 10.1016/j.revmed.2007.05.006 [17597259]

[13] Flacco ME, Manzoli L, Ioannidis JPA. Noninferiority is almost certain with lenient noninferiority margins. J Clin Epidemiol 2016;71:118 10.1016/j.jclinepi.2015.11.010 [26607237]

[14] Rehal S, Morris TP, Fielding K, et al. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ open 2016;6:e012594 10.1136/bmjopen-2016-012594 [27855102]

[15] Le Henanff A, Giraudeau B, Baron G, et al. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 2006;295:1147–51 10.1001/jama.295.10.1147 [16522835]

[16] Wangge G, Klungel OH, Roes KCB, et al. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS ONE 2010;5:e13550 10.1371/journal.pone.0013550 [21048948]

[17] Hays M, Andrews M, Wilson R, et al. Reporting quality of randomised controlled trial abstracts among high-impact general medical journals: a review and analysis. BMJ open 2016;6:e011082 10.1136/bmjopen-2016-011082 [27470506]